CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2011	Sep. 30, 2010	Sep. 30, 2011	Sep. 30, 2010
Revenue
Housing	$ (6,519)	$ 118,076	$ (6,519)	$ 254,525
Commercial rental	0	0	0	0
Tissue array products	153,228	150,399	390,458	353,336
Total revenue	146,709	268,475	383,939	607,861
Cost of Sales
Housing	58,625	116,808	58,625	250,601
Commercial rental	16,195	0	47,947	0
Tissue array products	104,848	95,818	294,172	261,770
Total cost of sales	179,668	212,626	400,744	512,371
Gross Profit	(32,959)	55,849	(16,805)	95,490
Operating Expenses:
Salaries and wages	45,581	42,655	127,157	431,690
Depreciation and amortization	37,516	35,599	110,509	106,332
Bad debt expense	23,526	42,179	92,356	84,123
Loss from contingent liabilities	36,942	0	36,942	0
Professional fees	14,268	11,464	71,376	44,350
Selling and distribution expenses	6,211	10,956	16,422	28,922
Other general and administrative expenses	53,660	62,260	105,422	130,602
Research and development expenses	0	29	0	10,186
Total Operating Expenses	217,704	205,142	560,184	836,205
Loss from Operations	(250,663)	(149,293)	(576,989)	(740,715)
Other Income (Expense)
Interest income (expense)	1,328	(396)	3,978	878
Other income (expense), net	(6,370)	(973)	(9,389)	26,545
Total Other Income (Expense), Net	(5,042)	(1,369)	(5,411)	27,423
Loss before Income Taxes	(255,705)	(150,662)	(582,400)	(713,292)
Income Tax Benefit (Expense)	0	0	0	0
Net loss	(255,705)	(150,662)	(582,400)	(713,292)
Net loss attributable to the noncontrolling interest	(61,720)	(27,324)	(114,889)	(64,464)
Net loss attributable to CYBRDI, INC. AND SUBSIDIARIES	$ (193,985)	$ (123,338)	$ (467,511)	$ (648,828)
Net Loss Per Common Share
Basic and Diluted	$ 0.00	$ 0.00	$ (0.01)	$ (0.01)
Weighted Average Number of Shares Outstanding
Basic and Diluted	91,780,528	65,756,567	74,431,221	64,963,234